CK-M

CK-M is a long-acting synthetic RNA polymer preparation developed by GenePharma for the treatment of male erectile dysfunction (ED). It is designed to be administered via intracavernosal injection to improve erectile function and sexual satisfaction. The therapy is currently being evaluated in prospective observational studies at the Boao Super Hospital in China, focusing on its safety, tolerability, and efficacy as measured by the International Index of Erectile Function (IIEF) scores. While the specific molecular target is not publicly detailed, the RNA polymer modality suggests a mechanism involving the modulation of local gene expression or physiological pathways essential for penile tumescence, potentially through the induction of endogenous growth factors or signaling molecules.

Other names

RNA polymer preparation CK-M